Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INVAGESIC FORTE vs ANEXSIA 7.5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Management of mild to moderate pain,Off-label: acute pain, dental pain, postoperative pain
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in Cr Cl <30 m L/min)
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9.
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates)
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature)
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
Oral: 80-100% (food delays absorption but does not reduce extent)
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis.
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects.
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 m L/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding.
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; risk from concomitant use with benzodiazepines or other CNS depressants; cytochrome P450 2D6 ultra-rapid metabolizers (risk of life-threatening respiratory depression from codeine).
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolism of codeine (CYP2D6); gastrointestinal bleeding (NSAIDs); cardiovascular thrombotic events; renal toxicity; hepatic impairment; elderly patients; pregnancy.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
Hypersensitivity to codeine, ibuprofen, or any component; patients with significant respiratory depression; acute or severe bronchial asthma (in an unmonitored setting or without resuscitative equipment); gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery; children <12 years old; breastfeeding (ultra-rapid metabolizers of codeine).
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
Avoid grapefruit juice as it may increase tramadol levels. High-fat meals may delay absorption but not overall effect. No specific dietary restrictions beyond avoiding alcohol.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
Diclofenac excreted in breast milk in low amounts (M/P ratio ~0.02-0.05); paracetamol M/P ratio ~1.0. Both considered compatible with breastfeeding at recommended doses. However, avoid if infant has hypersensitivity or G6PD deficiency. Monitor infant for sedation or respiratory depression if used with opioids.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
Increased renal clearance in pregnancy may reduce plasma levels; however, dose adjustments are not recommended due to fetal safety concerns. Use lowest effective dose for shortest duration. Avoid NSAIDs after 20 weeks gestation; if necessary, reduce dose and limit duration.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
Invagesic Forte (paracetamol 500 mg + tramadol 37.5 mg) is a fixed-dose combination analgesic. Tramadol is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy. Monitor for serotonin syndrome when used with SSRIs, SNRIs, or MAOIs. Maximum daily tramadol dose is 300 mg (8 tablets). Seizure risk increases in patients taking SSRIs, tricyclics, or with epilepsy.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
Take exactly as prescribed; do not exceed 8 tablets daily.,May cause dizziness or drowsiness; avoid driving or operating machinery.,Avoid alcohol while taking this medication.,Do not take with other medications containing acetaminophen (paracetamol) to avoid liver damage.,Report severe constipation, nausea, or difficulty breathing to your doctor.,Do not stop abruptly; withdrawal symptoms may occur.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INVAGESIC FORTE vs ANEXSIA 7.5/325, answered by our medical review team.
INVAGESIC FORTE is a Opioid Analgesic Combination that works by Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.. ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INVAGESIC FORTE and ANEXSIA 7.5/325 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INVAGESIC FORTE is: One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INVAGESIC FORTE and ANEXSIA 7.5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INVAGESIC FORTE is classified as Category C. Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester u. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.